Platelet Antibody Specificity Analyzed by Different Tests
|
By LabMedica International staff writers Posted on 09 Jun 2015 |
|
Image: Scanning electron micrograph of activated platelets (Photo courtesy of Bayer).
The detection of platelet antibodies plays a crucial role in the diagnosis of immunologic platelet disorders such as fetal/neonatal alloimmune thrombocytopenia (FNAIT) or refractoriness to platelet transfusions, influencing further therapeutic management.
The gold standard analysis for the determination of platelet antibodies, the “monoclonal antibody immobilization of platelet antigens” assay is restricted to specialized reference laboratories due to the laborious efforts involved and the consequent need for freshly prepared test platelet.
Hematologists at the Medical University of Graz (Austria) analyzed serum samples from 1,234 patients with a median age of 58.2 years and 573 were female and 661 male. The serum samples were tested for Human Leukocyte Antigen (HLA) or platelet-specific antibodies. The scientists routinely use two commercially available test methods, an antigen capture ELISA and a solid-phase assay. For the confirmation and specification of anti-HLA class I antibodies, a complement-dependent lymphocytotoxicity test is additionally performed.
All serum samples were analyzed by enzyme-linked immunosorbent assays (ELISA), either Lifecodes PAKPLUS or PAK12 (Gen-Probe; Waukesha, WI, USA), and by a solid-phase assay (Capture-P Ready Screen, Immucor Inc.; Norcross, GA, USA), and in specified cases by a specific lymphocytotoxicity test (LCT, Bio-Rad Medical Diagnostics GmbH; Dreieich, Germany). The LCT was performed in cases of clinically suspected or, by the described assays detected, HLA class I antibodies.
Platelet antibodies were detected in 366 of 1,234 samples (29.7%). In 70.3% concordant negative, but only in 8.4% concordant positive results were obtained with both the methods; 185 of 1,053 in the solid-phase assay negative samples were positive in the ELISA (15.0%). In samples positive in both methods, most antibodies reacted against HLA class I antigens. Glycoprotein (GP) specific platelet antibodies were more frequently detectable in the ELISA than in the solid-phase assay, whereas weakly positive results have to be interpreted cautiously.
The authors concluded that because ELISA, solid-phase assay, and LCT showed highly divergent results and only for detecting soluble platelet antibodies, and due to several limitations. The additional analysis by the “monoclonal antibody-specific immobilization of platelet antigen” (MAIPA) assay is highly recommended. The study was published on May 5, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Medical University of Graz
Gen-Probe
Immucor Inc.
The gold standard analysis for the determination of platelet antibodies, the “monoclonal antibody immobilization of platelet antigens” assay is restricted to specialized reference laboratories due to the laborious efforts involved and the consequent need for freshly prepared test platelet.
Hematologists at the Medical University of Graz (Austria) analyzed serum samples from 1,234 patients with a median age of 58.2 years and 573 were female and 661 male. The serum samples were tested for Human Leukocyte Antigen (HLA) or platelet-specific antibodies. The scientists routinely use two commercially available test methods, an antigen capture ELISA and a solid-phase assay. For the confirmation and specification of anti-HLA class I antibodies, a complement-dependent lymphocytotoxicity test is additionally performed.
All serum samples were analyzed by enzyme-linked immunosorbent assays (ELISA), either Lifecodes PAKPLUS or PAK12 (Gen-Probe; Waukesha, WI, USA), and by a solid-phase assay (Capture-P Ready Screen, Immucor Inc.; Norcross, GA, USA), and in specified cases by a specific lymphocytotoxicity test (LCT, Bio-Rad Medical Diagnostics GmbH; Dreieich, Germany). The LCT was performed in cases of clinically suspected or, by the described assays detected, HLA class I antibodies.
Platelet antibodies were detected in 366 of 1,234 samples (29.7%). In 70.3% concordant negative, but only in 8.4% concordant positive results were obtained with both the methods; 185 of 1,053 in the solid-phase assay negative samples were positive in the ELISA (15.0%). In samples positive in both methods, most antibodies reacted against HLA class I antigens. Glycoprotein (GP) specific platelet antibodies were more frequently detectable in the ELISA than in the solid-phase assay, whereas weakly positive results have to be interpreted cautiously.
The authors concluded that because ELISA, solid-phase assay, and LCT showed highly divergent results and only for detecting soluble platelet antibodies, and due to several limitations. The additional analysis by the “monoclonal antibody-specific immobilization of platelet antigen” (MAIPA) assay is highly recommended. The study was published on May 5, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Medical University of Graz
Gen-Probe
Immucor Inc.
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Gel Cards
DG Gel Cards
Human Estradiol Assay
Human Estradiol CLIA Kit
Latest Hematology News
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
Interstitial Lung Disease Test Could Identify Patients Before Symptoms Appear
Interstitial lung disease (ILD) is a group of chronic respiratory disorders that cause inflammation and scarring of lung tissue, often leading to irreversible damage and the need for lung transplants.... Read more
Genomic-First Approach Identifies Rare Genetic Disorders Earlier
Rare genetic disorders (RGDs) affect more than 24 million people in the US, yet many cases remain undiagnosed due to the limitations of traditional testing methods. Current diagnosis typically follows... Read more
Immunology
view channel
Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Luminescent Probe Measures Immune Cell Activity in Real Time
The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more
Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more
Microbiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read more
Pathology
view channel
New Imaging Tech to Improve Diagnosis and Treatment of Skin Cancers
Skin cancer is the most common malignancy worldwide, and accurately assessing tumor invasion or treatment response remains a major clinical challenge. Current imaging methods, such as confocal microscopy... Read more
Serially Testing Brain Tumor Samples Reveals Treatment Response in Glioblastoma Patients
Glioblastoma (GBM) is the most aggressive form of brain cancer, known for rapid growth, recurrence, and resistance to treatment. Understanding how tumors respond to therapy remains challenging since imaging... Read more
High-Accuracy Tumor Detection Method Offers Real-Time Surgical Guidance
Pancreatic neuroendocrine neoplasms (PNENs) are rare cancers that affect hormone-producing cells in the pancreas. Although uncommon, their incidence has been increasing, and surgery remains the only curative option.... Read more
Technology
view channel
AI Algorithm Assesses Progressive Decline in Kidney Function
Chronic kidney disease (CKD) affects more than 700 million people worldwide and remains a major global health challenge. The condition often progresses silently, and many patients remain undiagnosed until... Read more
Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. What makes it particularly insidious is that flu viruses are contagious even before... Read more
3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. However, traditional biosensing technologies struggle with achieving this at the micro-scale,... Read more
Industry
view channel
Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
Blood processing and storage are vital to healthcare and clinical practice, ensuring safe transfusions and cellular therapies. However, hospitals and laboratories worldwide face challenges in maintaining... Read more